Policy & Regulation
Vertex Inks Reimbursement Agreement in Spain for Kaftrio in Combination with Ivacaftor to Treat People With Cystic Fibrosis 12 Years and Older With At Least One F508del Mutation in the CFTR Gene
24 November 2021 - - The Spanish government has approved terms for the national reimbursement of Kaftrio (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor for the treatment of cystic fibrosis for eligible patients, US- and UK-based Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) said.

The agreement covers people with CF ages 12 years and older who have at least one copy of the F508del mutation, regardless of the other mutation type in the CFTR gene.

Kaftrio (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor can be prescribed to eligible patients by treating physicians once the medicine is listed in the national Official Gazette Nomenclator.

With this agreement, Spain joins the group of over 25 countries, such as Ireland, Germany, Austria, Slovenia, Croatia, Luxembourg, Denmark, Finland, France, Portugal, Italy, Switzerland and the UK, where eligible patients with CF have access to the triple combination therapy.

Kaftrio (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor is approved in the European Union for the treatment of cystic fibrosis in patients ages 12 years and older who have at least one copy of the F508del mutation in the CFTR gene.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London.
Login
Username:

Password:


Related Headlines